RUSH

Access DB# 14564

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Kalsay Habte Examiner #: 78271 Date: May 20, 2003
Art Unit: 1624 Phone Number 308-4315 Serial Number: 10/088,088
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Amide Compounds

Inventors (please provide full names): _____

Point of Contact:
Susan Hanley
Technical Info. Specialist
CM1 6B05 Tel: 305-4053

Earliest Priority Filing Date: 10/01/1999

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**



R^3 = phenyl sub with

R^1 = Imidazolyl

R^3 =  sub with 

R^2 = H, lower Alkyl

R^3 = 

R^3 = 
X = C
X = N

R^3 = 

* Apts elected
R^1 = imidazolyl

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Hanley	NA Sequence (#) _____	STN $310
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) 1	Questel/Orbit _____
Date Searcher Picked Up: 5/20	Bibliographic _____	Dr.Link _____
Date Completed: 5/21	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: 30	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: 45	Other _____	Other (specify) _____

PTO-1590 (1-2000)

L Number	Hits	Search Text	DB	Time stamp
1	3878	548/312.1, 548/314.7, 548/315.1, 548/338.1, 514/397, 514/399	USPAT	2003/05/21 14:47
2	61	(548/312.1, 548/314.7, 548/315.1, 548/338.1, 514/397, 514/399) and 5HT	USPAT	2003/05/21 14:48
3	173	(548/312.1, 548/314.7, 548/315.1, 548/338.1, 514/397, 514/399) and 5-HT$	USPAT	2003/05/21 14:48

search in Registry & Ca Old


```
=> d que l31
L14              STR

            6
            O
            ||
Hy~Cb~NH~C~Cy
1  2  3  4  5


NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT   1
GGCAT   IS MCY  UNS  AT   2
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E3 C  E2 N  AT   1
ECOUNT  IS E6 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   6

STEREO ATTRIBUTES: NONE
L16       67144 SEA FILE=REGISTRY ABB=ON  PLU=ON  16.195.22/RID AND 46.150.18/R
                ID AND NRS>2 AND N>2 AND O/ELS NOT PMS/CI
L19         781 SEA FILE=REGISTRY SUB=L16 SSS FUL L14
L25             STR

            6
            O                Cb~Hy      Hy~Hy      Hy~Cb   Cb @14   Hy @15
            ||               @7  @8     @10 11     @12  24
Hy~Cb~NH~C~G1
1  2  3  4  5


Hy~Ak   Cb~Cb~~X                        Hy~Cb
@16  23  @18 17   19                    @22  25


VAR G1=7/8/10/12/14/15/16/18/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT   1
GGCAT   IS MCY  UNS  AT   2
GGCAT   IS MCY  UNS  AT   7
GGCAT   IS MCY  UNS  AT   8
GGCAT   IS MCY  UNS  AT  10
GGCAT   IS MCY  UNS  AT  11
GGCAT   IS MCY  UNS  AT  12
GGCAT   IS PCY  UNS  AT  14
GGCAT   IS PCY  UNS  AT  15
GGCAT   IS PCY  UNS  AT  16
GGCAT   IS MCY  UNS  AT  17
GGCAT   IS MCY  UNS  AT  18
GGCAT   IS MCY  UNS  AT  22
GGCAT   IS MCY  UNS  AT  24
GGCAT   IS MCY  UNS  AT  25
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E3 C  E2 N  AT   1
ECOUNT  IS E6 C  AT   2
ECOUNT  IS E6 C  AT   7
ECOUNT  IS E4 C  E1 S  AT   8
```

Same STR search as for L30

```
ECOUNT  IS E4 C  E1 S  AT  10
ECOUNT  IS E4 C  E1 S  AT  11
ECOUNT  IS E3 C  E1 N  E1 S  AT  12
ECOUNT  IS E13 C  AT  14
ECOUNT  IS E12 C  E1 N  AT  15
ECOUNT  IS E8 C  E1 N  AT  16
ECOUNT  IS E6 C  AT  17
ECOUNT  IS E6 C  AT  18
ECOUNT  IS E4 C  E1 N  AT  22
ECOUNT  IS E6 C  AT  24
ECOUNT  IS E6 C  AT  25

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  21

STEREO ATTRIBUTES: NONE
L26          102 SEA FILE=REGISTRY SUB=L19 SSS FUL L25
L30            0 SEA FILE=CAOLD ABB=ON PLU=ON L26
```

102 cpds

no hits in Caold

=> d ibib abs hitstr l30 1-12

L30 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:947029 CAPLUS
DOCUMENT NUMBER: 138:24705
TITLE: Preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compounds as neuropeptide Y antagonists.
INVENTOR(S): Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Pat. Appl. 2002 52,371.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002188124	A1	20021212	US 2002-92549	20020308
JP 2003104884	A2	20030409	JP 2002-271261	20000817
US 6326375	B1	20011204	US 2000-640784	20000818
US 6335345	B1	20020101	US 2001-928431	20010814
US 2002052371	A1	20020502	US 2001-983598	20011025
US 6388077	B2	20020514		
US 6462053	B1	20021008	US 2002-101221	20020320
US 2002165391	A1	20021107		
US 2003055251	A1	20030320	US 2002-226225	20020823

PRIORITY APPLN. INFO.:
JP 1999-233573 A 19990820
JP 2000-137692 A 20000510
US 2000-640784 A3 20000818
US 2001-983598 A2 20011025
JP 2000-247145 A3 20000817
US 2002-101221 A3 20020320

OTHER SOURCE(S): MARPAT 138:24705
GI



I

AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = CH, CH(OH); Y = (substituted) imino, O], were prepd. Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in

PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80.degree. for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80.degree. for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide (II), which inhibited [125I]neuropeptide Y binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.

IT **328232-32-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compds. as neuropeptide Y antagonists)

RN 328232-32-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[4-(1-ethyl-1H-imidazol-2-yl)phenyl]-3-oxo- (9CI) (CA INDEX NAME)



L30 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:10470 CAPLUS
DOCUMENT NUMBER: 136:85810
TITLE: Preparation of arylamides and heterocyclylamides as factor Xa inhibitors for treatment of thromboembolic disorders
INVENTOR(S): Quan, Mimi L.; Lam, Patrick Y.; Li, Yunlong; Pinto, Donald J. P.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002000651	A2	20020103	WO 2001-US20538	20010627
WO 2002000651	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-214758P P 20000627
US 2000-246124P P 20001106

OTHER SOURCE(S): MARPAT 136:85810

GI



I



II



III

AB Title compds. I and II [wherein ring M, including M1, M2, and, if present, M3 = 5-membered arom. heterocycle substituted with 0-2 R1a; or ring M = isoxazoline, isothiazoline, pyrazoline, triazoline, or tetrazoline substituted with 0-2 R1a; R1a = H, (un)substituted alkyl, alkenyl, amino, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amido, alkoxycarbonylamino, aminocarboxy, etc.; G = 5-6 membered (hetero)cycle optionally fused to Ph, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl substituted with 0-2 R; R = H, alkyl, halo, OH, alkoxy, CN, (un)substituted carboximidamido, (alkyl)amino, OCF3, etc.; Z = a bond, (un)substituted (CH2)1-4, (CH2)pO(CH2)q, (CH2)pCO(CH2)q, (CH2)pOCO(CH2)q, (CH2)pCO2(CH2)q, (CH2)pNH(CH2)q, etc.; p + q = 0-2; Z1 = (un)substituted (CH2)1-5, (CH2)0-2CH=CH(CH2)0-2, (CH2)0-2C.tplbond.C(CH2)0-2, (CH2)uCO(CH2)w, (CH2)uCO2(CH2)w, (CH2)uO(CH2)w, (CH2)uNH(CH2)w, etc.; u + w = 0-4; A = (un)substituted carbocycle or heterocycle; B = H, Y, or XY; X = (un)substituted (CH2)1-4, CO, C(NH), CH(NH2), CH(OH), CH(SH), COCH2, CH2CO, S, SO, SO2, NHCO, CONH, O, etc.; Y = (un)substituted carbocycle or heterocycle] were prepd. as inhibitors of trypsin-like serine protease enzymes, esp. factor Xa. For example, 4-biphenylcarboxaldehyde oxime

(prepn. given) was treated with itaconic acid monomethyl ester and bleach in THF to give 3-([1,1']-biphen-4-yl)-5-(carbomethoxymethyl)isoxazolin-5-ylcarboxylic acid (84%). Amidation with 3-cyanoaniline (28%), followed by conversion to the amidine and elution with TFA, afforded III.bul.TFA. Some of the invention compds. inhibited factor Xa with Ki values of .ltoreq. 10 .mu.M. Thus, I and II are useful as anticoagulant agents for treatment and prevention of thromboembolic disorders.

IT **385831-50-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of arylamides and heterocyclylamides as factor Xa inhibitors for treatment of thromboembolic disorders)

RN 385831-50-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 1-(3-cyano-4-fluorophenyl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:851122 CAPLUS
DOCUMENT NUMBER: 135:371759
TITLE: Preparation of N-imidazolylphenyl-5,6-dihydrobenzo[h]quinazolin-4-amines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders
INVENTOR(S): Yamada, Akira; Spears, Glen; Hayashida, Hisashi; Tomishima, Masaki; Ito, Kiyotaka; Imanishi, Masashi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087845	A2	20011122	WO 2001-JP4002	20010514
WO 2001087845	A3	20020829		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2000-7501 A 20000515
AU 2000-1955 A 20001207

OTHER SOURCE(S): MARPAT 135:371759

GI



II

AB Title compds. AMQNHZ [I; wherein A = H, (un)substituted, unsatd., N-contg. heterocyclic group, or C(NH)NHR; R = (un)substituted aryl or heterocyclic group; M = (CH2)n, (CH2)nO(CH2)m, or (CH2)nNH(CH2)m; n and m = independently 0-2; Q = (un)substituted cycloalkylene group, arylene, or divalent heterocyclic group; Z = (un)substituted, unsatd., mono-, di-, tri-, or tetra-cyclic, N-contg. heterocyclic group which may contain addnl. N, O, and S atoms as the ring member(s), e.g. indeno[1,2,3-de]phthalazinyl or 5,6-dihydrobenzo[h]quinazolinyl; and the prodrugs or pharmaceutically acceptable salts thereof] were prepd. For example, a mixt. of 4-chloro-5,6-dihydrobenzo[h]quinazoline, 3-(1,2-dimethyl-1H-imidazol-5-yl)aniline, and 1,3-dimethyl-2-imidazolidinone was heated for an hour at 200.degree.C, cooled, treated with 1N aq. NaOH and water, and worked up to give II. I are 5-hydroxytryptamine (5-HT) antagonists useful for the prevention and/or treatment of central nervous system (CNS) disorders, such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse, schizophrenia, and disorders assocd. with spinal trauma and/or head injury (no data).

IT **374554-94-6P**, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-3-(3-thienyl)benzamide **374554-95-7P**, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-3-(2-thienyl)benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-contg. heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

RN 374554-94-6 CAPLUS

CN Benzamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-3-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 374554-95-7 CAPLUS
CN Benzamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-3-(2-thienyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:713321 CAPLUS
DOCUMENT NUMBER: 135:272956
TITLE: Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
INVENTOR(S): Betageri, Rajashekhar
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070703	A2	20010927	WO 2001-US9262	20010322
WO 2001070703	A3	20020523		

W: CA, JP, MX
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.: US 2000-533207 A 20000323
OTHER SOURCE(S): MARPAT 135:272956
GI



I



II



III

AB Title compds. I and II are disclosed [wherein R1, R2 = CF3, halo, cyano, branched or unbranched C1-8 alkyl or alkenyl, (un)substituted C3-8 cycloalkyl, C1-8 alkoxy, C1-4 alkyloxyalkyl, C1-8 alkylthio, C1-4 alkylthioalkyl, C1-8 dialkylamino, C1-4 dialkylaminoalkyl, CO2R4 [R4 = C1-4 alkyl or C1-4 alkenyl (un)substituted with carbocyclyl or heterocyclyl], (un)substituted aryl or heterocyclyl; L = NHC(O), NHC(O)O, NHC(O)C(O), NHC(S), NH, NHC(O)NH, NHC(S)NH, NHCH2, NHCH(R5) [where R5 = H, cyano, C1-6 alkyl, C1-6 alkyloxyoalkyl, C1-6 alkythioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkysulfonylalkyl, C3-6 cycloalkyl, (un)substituted heterocyclyl or aryl, NHC(R5)-lower alkyl]; R3 = C1-8 alkyl, alkoxy, alkylthio, or alkylamino, C1-4 alkoxyalkyl, alkylthioalkyl, alkylaminoalkyl, dialkylalkylaminoalkyl, carbo- or heterocyclyl [carbo- or heterocyclyl (un)substituted with 1 or more of the following: halo, CN, NO2, SO2NH2, or R6 (where R6 = Ph, heterocyclyl, C3-6 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkyloxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, or alkylsulfonylalkyl, or C2-6 alkynyl), and R6 is (un)substituted with halo, OH, alkoxy, CN, COO-lower alkyl, CONH-lower alkyl, CON-(lower alkyl)2, dialkylamino, Ph, or heterocyclyl]; or R3 = CO2R6, N(R6)2, NH(R6), C(O)R6, OR6, S(O)0-2R6, SO2NHR6, or SO2N(R6)2; or a pharmaceutically acceptable deriv. thereof]. The compds. have antiinflammatory and immunosuppressive activity by virtue of their ability to inhibit IL-2 prodn. in T-lymphocytes. Twenty compds. were individually claimed, and 3 examples were prepd. in examples. For instance, 4-methyl-2-phenylimidazole was condensed with 1-fluoro-4-nitrobenzene in DMSO contg. KOBu-tert (80%), and the product was reduced with SnCl2 in AcOH and amidated with 4-chlorobenzoic acid (70%) to give title compd. III. In an IL-2 promoter assay measuring transcriptional activation of a luciferase reporter gene, III and the other synthetic example compds. had IC50 values below 10 .mu.M.

IT **362613-46-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of substituted (aminophenyl)imidazoles and their use as anti-inflammatory agents)

RN 362613-46-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[2-ethyl-4-(3-pyridinyl)-1H-imidazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:693264 CAPLUS
DOCUMENT NUMBER: 135:257269
TITLE: Preparation of N-heterocyclyl amide compounds as 5-HT antagonists
INVENTOR(S): Yamada, Akira; Tomishima, Masaki; Hayashida, Hisashi; Imanishi, Masashi; Spears, Glen W.; Ito, Kiyotaka; Takahashi, Fumie; Miyake, Hiroshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068585	A1	20010920	WO 2001-JP1993	20010313
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041128	A5	20010924	AU 2001-41128	20010313
EP 1264820	A1	20021211	EP 2001-912338	20010313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: JP 2000-70127 A 20000314
JP 2000-305947 A 20001005
WO 2001-JP1993 W 20010313
OTHER SOURCE(S): CASREACT 135:257269; MARPAT 135:257269

AB Amides compds. represented by the general formula R1-A-X-NHCO-Y-R2 [wherein R1 is an optionally substituted heterocyclic group or optionally substituted phenyl; R2 is optionally substituted fused Ph, optionally substituted Ph, or optionally substituted thienyl; A is a group represented by the formula -(CH2)t-(O)m- or -(CR3R4)pNR5(CO)n- (wherein R3 and R4 each is hydrogen or R3 and R4 in combination form imino; R5 is hydrogen or lower alkyl; t is 0, 1, or 2; and p, m, and n each is 0 or 1); X is optionally substituted phenylene or an optionally substituted, divalent, nitrogenous heterocyclic group; and Y is a bond, lower alkylene, or lower alkenylene] and salts thereof are prepd. Theses amides include phenylacetamide, cinnamides, 1H-indole-7-carboxamides, 3-(2-pyridyl)-2-propenamides, 5-phenyl-2-thiophenecarboxamides, 9H-carbazolecarboxamides, 3-phenyl-2-propenamides, 9H-fluorene-1-carboxamides, 2,3-dihydrobenz[b]oxepine-4-carboxamides,

1H-benzo[b]thiepin-4-carboxamides, and 3-(1H-indol-3-yl)-2-propenamides. They are antagonists of 5-hydroxytryptamine (5-HT), in particular 5-HT2c, and are useful for the treatment of 5-HT-mediated diseases such as (1) central nervous system disorders in including anxiety, depression, obsessive-compulsive neurosis, migraine headache, anorexia, Alzheimer's disease, sleep disorder, over-eating, and panic, (2) withdrawal symptom caused by cocaine, ethanol, nicotine, and benzodiazepine, (3) schizophrenia, (4) spinal cord injury, and /or (5) head injury such as hydrocephalus. Thus, SOCl2 was added to a soln. of (E)-4-phenyl-3-butenoic acid in benzene, heated under reflux for 1 h, and cooled, followed by adding 3-(imidazol-1-yl)aniline and Et3N, and the resulting mixt. was stirred at room temp. for 1 h to give (3E)-N-[3-(imidazol-1-yl)phenyl]-4-phenyl-3-butenamide (I). I in vitro inhibited by 82% the binding of [3H]mesulergine to 5-HT2c receptor which was prepd. from rat frontal lobe cortex.

IT **361551-65-7P 361551-66-8P 361551-67-9P**
361551-68-0P 361551-70-4P 361551-71-5P
361551-72-6P 361551-73-7P 361551-74-8P
361551-75-9P 361551-76-0P 361551-77-1P
361551-78-2P 361551-79-3P 361551-80-6P
361551-81-7P 361551-82-8P 361551-83-9P
361552-39-8P 361552-40-1P 361552-41-2P
361552-42-3P 361552-43-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central nervous system disorders, drug withdrawal symptom, schizophrenia, spinal code injury, and head injury)

RN 361551-65-7 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 361551-66-8 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-67-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 361551-68-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-70-4 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 361551-71-5 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 361551-72-6 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-73-7 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 361551-74-8 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 361551-75-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-chloro-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-76-0 CAPLUS

CN 9H-Carbazole-1-carboxamide, N-[3-chloro-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-77-1 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-chloro-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 361551-78-2 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)-5-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 361551-79-3 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)-5-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 361551-80-6 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)-5-methoxyphenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 361551-81-7 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-cyano-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-82-8 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(5-chloro-4-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361551-83-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(5-chloro-4-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361552-39-8 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1-ethyl-2-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361552-40-1 CAPLUS
CN Benzamide, N-[3-(1-ethyl-2-methyl-1H-imidazol-5-yl)phenyl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 361552-41-2 CAPLUS
CN Benzamide, 3-(5-chloro-2-thienyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 361552-42-3 CAPLUS
CN Benzamide, N-[3-[2-(difluoromethyl)-1-methyl-1H-imidazol-5-yl]phenyl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 361552-43-4 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-[2-(difluoromethyl)-1-methyl-1H-imidazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:265412 CAPLUS
DOCUMENT NUMBER: 134:280863
TITLE: Preparation of amides as 5-HT antagonists
INVENTOR(S): Ito, Kiyotaka; Spears, Glen W.; Takahashi, Fumie; Yamada, Akira; Tomishima, Masaki; Miyake, Hiroshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025229	A1	20010412	WO 2000-JP6623	20000926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014640	A	20020611	BR 2000-14640	20000926
EP 1216240	A1	20020626	EP 2000-961234	20000926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511380	T2	20030325	JP 2001-528173	20000926

PRIORITY APPLN. INFO.: AU 1999-3198 A 19991001
WO 2000-JP6623 W 20000926

OTHER SOURCE(S): MARPAT 134:280863
GI



I



II

AB The title compds. [I; R1 = (un)substituted N-contg. heterocyclic group selected from imidazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl; R2 = H, alkyl; R3 = Ph substituted with thienyl or halophenyl, thienyl group substituted with thienyl, Ph or halophenyl, etc.] which have 5-HT antagonism activity, were prepd. Thus, reacting 3-(pyridin-3-

yl)aniline with fluorene-1-carbonyl chloride in the presence of pyridine in CH2Cl2 afforded 87.6% II which showed 74% inhibition of 5-HT2c receptor binding.

IT **333792-48-6P 333792-76-0P 333792-84-0P**
333792-94-2P 333792-97-5P 333793-02-5P,
N-[3-(2,3-Dimethyl-3H-imidazol-4-yl)-phenyl]-4'-fluorobiphenyl-3-carboxamide **333793-07-0P 333793-28-5P**
333793-30-9P 333793-32-1P, N-[3-(Imidazol-1-yl)phenyl]-2-phenylthiazole-4-carboxamide **333793-41-2P 333793-47-8P**
, N-[3-(4-Methylimidazol-1-yl)-phenyl]-9H-fluorene-1-carboxamide **333793-49-0P**, N-[3-(4,5-Dimethylimidazol-1-yl)-phenyl]-9H-fluorene-1-carboxamide **333793-51-4P**, N-[3-(4,5-Dimethylimidazol-1-yl)-phenyl]-3-(2-thienyl)benzamide **333793-54-7P**,
N-[3-(1,2-Dimethylimidazol-5-yl)phenyl]-6-fluoro-9H-carbazole-1-carboxamide **333793-55-8P**, N-[3-(4,5-Dimethylimidazol-1-yl)-phenyl]-2,3-dimethyl-1H-indole-7-carboxamide **333793-56-9P**,
N-[3-(4,5-Dimethylimidazol-1-yl)-phenyl]-6-fluoro-9H-carbazole-1-carboxamide **333793-57-0P**, N-[3-(4-Methylimidazol-1-yl)phenyl]-9H-carbazole-1-carboxamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides as 5-HT antagonists)

RN 333792-48-6 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 333792-76-0 CAPLUS
CN Benzamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 333792-84-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 333792-94-2 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-3-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 333792-97-5 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 333793-02-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 333793-07-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 333793-28-5 CAPLUS
CN [2,2'-Bithiophene]-5-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 333793-30-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 333793-32-1 CAPLUS
CN 4-Thiazolecarboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 333793-41-2 CAPLUS

CN 9H-Carbazole-1-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 333793-47-8 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(4-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 333793-49-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 333793-51-4 CAPLUS
CN Benzamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 333793-54-7 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 333793-55-8 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 333793-56-9 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 333793-57-0 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(4-methyl-1H-imidazol-1-yl)phenyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:152682 CAPLUS
DOCUMENT NUMBER: 134:207809
TITLE: Preparation of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines, and related compounds as neuropeptide Y antagonists.
INVENTOR(S): Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014376	A1	20010301	WO 2000-JP5427	20000811

W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ,

LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU,
SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000013423	A	20020507	BR 2000-13423	20000811	
EP 1204663	A1	20020515	EP 2000-951971	20000811	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2002030086	A2	20020129	JP 2000-247145	20000817	
JP 2003104884	A2	20030409	JP 2002-271261	20000817	
BG 106390	A	20021229	BG 2002-106390	20020206	
NO 2002000814	A	20020415	NO 2002-814	20020219	
US 2003055251	A1	20030320	US 2002-226225	20020823	

PRIORITY APPLN. INFO.:

JP 1999-233573	A	19990820
JP 2000-137692	A	20000510
WO 2000-JP5427	W	20000811
JP 2000-247145	A3	20000817
US 2000-640784	A3	20000818
US 2001-983598	A3	20011025
US 2002-101221	A3	20020320

OTHER SOURCE(S): MARPAT 134:207809

GI



I

AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = N, CH; Y = (substituted) imino], were prepd. Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80.degree. for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80.degree. for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide, (II), which inhibited [125I]peptide YY binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.

IT **328232-32-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines, and related compds. as neuropeptide Y antagonists)

RN 328232-32-2 CAPLUS

CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[4-(1-ethyl-1H-imidazol-2-yl)phenyl]-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:121819 CAPLUS
DOCUMENT NUMBER: 132:161255
TITLE: Phenylimidazole derivatives as antihyperlipidemics and antiarteriosclerotics
INVENTOR(S): Mochizuki, Nobuo; Uchida, Seiichi; Yamada, Yuichi; Umeda, Nobihiro
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000053570	A2	20000222	JP 1998-222158	19980805

PRIORITY APPLN. INFO.: JP 1998-222158 19980805
OTHER SOURCE(S): MARPAT 132:161255
GI



I

AB Phenylimidazole derivs. [I, R1 = H, Me; R2 = H, Me, Et, CF3, OMe, Cl; A = alkylene; B = CH2CH2; D = substituted phenyl; X = CO, SO2; Y = O, S, SO2,

NMe, NH, N(CH2Ph), CONH, CON(Me); m, n, p = 0-1] and their pharmaceutically acceptable salts are claimed as antihyperlipidemics, and antiarteriosclerotics, with min. toxicity. I were prepd., and the acute toxicity of one of I was tested in rats. Examples of I tablets were formulated.

IT **259130-02-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylimidazole derivs. as antihyperlipidemics and antiarteriosclerotics)

RN 259130-02-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Cl

L30 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:98525 CAPLUS
DOCUMENT NUMBER: 132:137396
TITLE: Phenylazole compounds, process for producing the same and drugs for hyperlipemia
INVENTOR(S): Umeda, Nobuhiro; Mochizuki, Nobuo; Uchida, Seiichi; Nishibe, Tadayuki; Yamada, Hirokazu; Ito, Kunihito; Horikoshi, Hiromi
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006550	A1	20000210	WO 1999-JP4070	19990729
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339123	AA	20000210	CA 1999-2339123	19990729
AU 9949297	A1	20000221	AU 1999-49297	19990729
AU 753360	B2	20021017		
EP 1101759	A1	20010523	EP 1999-933152	19990729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000290280	A2	20001017	JP 1999-216581	19990730
JP 2000281656	A2	20001010	JP 1999-221789	19990804
JP 2000281658	A2	20001010	JP 1999-221790	19990804
US 6342516	B1	20020129	US 2001-744786	20010126

PRIORITY APPLN. INFO.:
JP 1998-218316 A 19980731
JP 1998-222157 A 19980805
JP 1999-16846 A 19990126
JP 1999-19670 A 19990128
JP 1999-24318 A 19990201
WO 1999-JP4070 W 19990729

OTHER SOURCE(S): MARPAT 132:137396
GI



I



II



III

AB Phenylpyrazole and phenylimidazole compds. represented by general formula (I; wherein A represents (un)substituted imidazolyl or pyrazolyl; B represents (un)substituted (CH2)k or (CH:CH)k; Y = bond, O, S, SO2, CO, OCH2, C1-5 alkyl-(un)substituted NHCO or NH; Z = (un)substituted and satd. or unsatd. heterocycle contg. 1 to 4 N, O or S atoms, (un)substituted benzoquinonyl or naphthoquinonyl) or pharmaceutically acceptable salts thereof are prepd. Claimed are drugs for hyperlipemia which contain these compds. I as the active ingredient. Among all, compds. wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too. Thus, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 1-(4-aminophenyl)imidazole 4.0, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 2.82, 1-hydroxybenzotriazole 2.72 g, and 2.5 mL Et3N were added to 30 mL DMF and stirred at room temp. for 20 h to give title compd. (II). II and N-[4-(imidazol-1-yl)phenyl]-1-methyl-3-pyrrrolecarboxamide (III) at 25 mg/kg p.o. lowered total serum level of cholesterol 40 and 75%, resp., and serum triglyceride level by 62 and 91%, resp. A tablet formulation contg. I was prepd.

IT **256661-07-1P 256661-11-7P 256661-13-9P**
256661-72-0P 256661-78-6P 256661-85-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylazole compds. as hypolipidemics and inhibitors of lipid peroxide formation)

RN 256661-07-1 CAPLUS
CN 1H-Indole-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 256661-11-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-5-methoxy-1-methyl- (9CI) (CA INDEX NAME)



RN 256661-13-9 CAPLUS
CN 1H-Indole-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 256661-72-0 CAPLUS
CN 1H-Indole-3-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 256661-78-6 CAPLUS
CN 1H-Indole-3-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-5,6-dimethoxy-1-methyl- (9CI) (CA INDEX NAME)



RN 256661-85-5 CAPLUS
CN 6-Indolizinecarboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:62632 CAPLUS
DOCUMENT NUMBER: 132:93327
TITLE: Preparation of indolines as 5-hydroxytryptamine antagonists
INVENTOR(S): Ito, Kiyotaka; Spiers, Glen W.; Sasaki, Hiroshi; Takahashi, Fumie
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000026463	A2	20000125	JP 1999-179698	19990625

PRIORITY APPLN. INFO.: AU 1998-4438 19980701
OTHER SOURCE(S): MARPAT 132:93327
GI



I

AB The title compds. I [R1 = thiazolyl, etc.; R2 = H, halo, etc.; R3 = H, alkylthio; X = NH, etc.] are prepd. In an in vitro test for affinity for the 5-HT2c receptors, 1-[[3-(imidazol-1-yl)phenyl]carbamoyl]-5-methylthio-6-trifluoromethylindoline showed IC80 of 10-5 M.

IT **254980-85-3P 254980-89-7P 254980-92-2P**
254980-93-3P 254981-00-5P 254981-01-6P
254981-02-7P 254981-03-8P 254981-04-9P
254981-05-0P 254981-06-1P 254981-07-2P
254981-08-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolines as 5-hydroxytryptamine antagonists)

RN 254980-85-3 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1H-imidazol-1-yl)phenyl]-5-(methylthio)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 254980-89-7 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]-5-(methylthio)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 254980-92-2 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methyl-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 254980-93-3 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 254981-00-5 CAPLUS
CN 1H-Indole-1-carboxamide, 5-cyano-2,3-dihydro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 254981-01-6 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-4-methyl-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 254981-02-7 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-6-methyl-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 254981-03-8 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1-methyl-1H-imidazol-5-

yl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 254981-04-9 CAPLUS
CN 1H-Indole-1-carboxamide, 6-cyano-2,3-dihydro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 254981-05-0 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 254981-06-1 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1H-imidazol-1-yl)phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 254981-07-2 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1H-imidazol-1-yl)phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 254981-08-3 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[3-(1H-imidazol-1-yl)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:804348 CAPLUS
DOCUMENT NUMBER: 132:49960
TITLE: Preparation of amides as serotonin antagonists
INVENTOR(S): Ito, Kiyotaka; Spiers, Glen W.; Takahashi, Fumie; Yamada, Akira; Toshima, Masaaki; Miyake, Hiroshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11349572	A2	19991221	JP 1999-98969	19990406
PRIORITY APPLN. INFO.:			AU 1998-2858	19980407

OTHER SOURCE(S): MARPAT 132:49960
GI



I

AB The title compds. I [R1 = (un)substituted heterocyclic ring; R2 = H, alkyl, etc.; R3 = (un)substituted pyridyl, etc.], useful as serotonin antagonists (no data), are prepd. For example, N-[3-(imidazol-1-yl)phenyl]benzamide was prepd.

IT **252927-50-7P 252927-53-0P 252927-56-3P**
252927-58-5P 252927-67-6P 252927-70-1P
252927-72-3P 252927-74-5P 252927-77-8P
252927-78-9P 252927-82-5P 252927-90-5P
252927-93-8P 252927-95-0P 252927-96-1P
252927-97-2P 252927-98-3P 252928-00-0P
252928-03-3P 252928-13-5P 252928-16-8P
252928-17-9P 252928-18-0P 252928-30-6P
252928-31-7P 252928-32-8P 252928-33-9P
252928-34-0P 252928-35-1P 252928-39-5P
252928-40-8P 252928-41-9P 252928-42-0P
252928-43-1P 252928-51-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides as serotonin antagonists)

RN 252927-50-7 CAPLUS
CN 1H-Indole-4-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 252927-53-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252927-56-3 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252927-58-5 CAPLUS

CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-9-oxo- (9CI) (CA INDEX NAME)



RN 252927-67-6 CAPLUS
CN 9H-Fluorene-4-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252927-70-1 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-7-nitro- (9CI) (CA INDEX NAME)



RN 252927-72-3 CAPLUS
CN Benzamide, N-[3-(1H-imidazol-1-yl)phenyl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 252927-74-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-7-nitro-9-oxo- (9CI) (CA INDEX NAME)



RN 252927-77-8 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 252927-78-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)-4-methylphenyl]- (9CI) (CA INDEX NAME)



RN 252927-82-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, 7-amino-N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252927-90-5 CAPLUS
CN 9H-Fluorene-2-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252927-93-8 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 252927-95-0 CAPLUS
CN Benzoic acid, 3-[(9H-fluoren-1-ylcarbonyl)amino]-5-(1H-imidazol-1-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 252927-96-1 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[2-(methylthio)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 252927-97-2 CAPLUS
CN 9H-Fluorene-3-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252927-98-3 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)-5-[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 252928-00-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(5-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-03-3 CAPLUS
CN 9H-Fluorene-1-carboxamide, 7-chloro-N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-13-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-16-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 4'-chloro-N-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-17-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-18-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(2-ethyl-1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-30-6 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[1-(phenylmethyl)-1H-imidazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 252928-31-7 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-32-8 CAPLUS
CN 1H-Indole-7-carboxamide, 3-ethyl-N-[3-(1H-imidazol-1-yl)phenyl]-2-methyl-

(9CI) (CA INDEX NAME)



RN 252928-33-9 CAPLUS
CN 1H-Indole-7-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 252928-34-0 CAPLUS
CN 1H-Carbazole-8-carboxamide, 2,3,4,9-tetrahydro-N-[3-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-35-1 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-9-methyl- (9CI) (CA INDEX NAME)



RN 252928-39-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(2-methyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-40-8 CAPLUS
CN Benzoic acid, 3-[(9H-fluoren-1-ylcarbonyl)amino]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 252928-41-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)-5-(4-morpholinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-42-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-(1H-imidazol-1-yl)-5-[(phenylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 252928-43-1 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[(dimethylamino)carbonyl]-5-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 252928-51-1 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L30 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:50888 CAPLUS
DOCUMENT NUMBER: 104:50888
TITLE: Benzothiazinecarboxamides with antiarthritic activity
INVENTOR(S): Uhlendorf, Joachim; Leyck, Sigurd
PATENT ASSIGNEE(S): Nattermann, A., und Cie G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3407505	A1	19850905	DE 1984-3407505	19840301

PRIORITY APPLN. INFO.: DE 1984-3407505 19840301
OTHER SOURCE(S): CASREACT 104:50888
GI



I



II

AB Antiarthritic (no data) 2H-1,2-benzothiazine-3-carboxamides I [R1 = (un)substituted arom. or partially satd. heterocyclyl] were prepd. Thus, 2.7 g Me 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide and 1.4 g 2-amino-4,5-trimethylenethiazole were refluxed in xylene to give 1.9 g carboxamide I (R1 = II).

IT **99804-52-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiarthritic)

RN 99804-52-1 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



this is a falso drop, no good